Topics:

Ibritumomab Tiuxetan Radioimmunotherapy Improves Quality of Life in Patients With Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

Ibritumomab Tiuxetan Radioimmunotherapy Improves Quality of Life in Patients With Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

The impact of anticancer therapy on quality of life has been receiving increasing attention, particularly with diseases such as low-grade non-Hodgkin’s lymphoma (NHL), where palliation rather than cure is the primary objective of therapy. The Functional Assessment of Cancer Therapy-General (FACT-G) is a validated questionnaire that captures the major areas of patients’ subjective evaluation of the impact of their cancer on the following domains: physical, social, emotional, functional, and relationship with doctor (J Clin Oncol 11[3]:570-579, 1993). There are two to seven questions per domain, yielding a total score from 0 to 112.

We used the FACT-G survey to assess quality of life in a phase III randomized trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy vs rituximab (Rituxan) immunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed NHL. The phase III trial enrolled 73 patients on the ibritumomab tiuxetan arm and 70 patients on the rituximab arm, with the following baseline characteristics: median age, 59 years (range: 29 to 80 years); 51% female; largest tumor > 5 cm, 45%; bone marrow involvement, 39%; and International Prognostic Index intermediate/high or high-risk group, 12%.

FACT-G total scores and subscale scores were compared between baseline and 3 months posttherapy within each of the treatment arms. Three months was chosen because patients were most likely to be in a maximal response from either therapy at this point. Not all patients completed the questionnaires; 62% and 51% of patients on the ibritumomab tiuxetan and rituximab arms, respectively, completed both a baseline and a 3-month FACT-G survey.

Of note, the mean baseline FACT-G score, prior to treatment, was high in both treatment arms: 86.9 for ibritumomab tiuxetan and 90.7 for rituximab. At 3 months posttherapy, the ibritumomab tiuxetan group experienced a statistically significant increase in the FACT-G total score (86.9 to 93.3; P = .001); the increase for the rituximab arm was not statistically significant (90.7 to 93.4; P = .185). Patients on the ibritumomab tiuxetan arm also experienced statistically significant improvement in the following FACT-G subscales: emotional, physical, and functional well-being; the rituximab group experienced a statistically significant improvement in the emotional subscale.

CONCLUSION: Ibritumomab tiuxetan therapy results in a statistically significant improvement in patient self-assessed quality of life. Such information may help patients and physicians with their treatment decisions.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.